Research and Clinical Trials on Escitalopram (Lexapro, Cipralex)

Escitalopram (Lexapro, Cipralex) Clinical Research Trials

From our searchable database at ClinicalTrialsFeeds.org, this list includes all the latest information about clinical trials involving Escitalopram (Lexapro, Cipralex).

• Efficacy and Safety of Escitalopram in Patients With Generalized Anxiety Disorder
  Status: Recruiting, Condition Summary: Generalized Anxiety Disorder
• Short-term Study of Combination Treatment of Escitalopram and Gaboxadol in Major Depressive Disorder
  Status: Recruiting, Condition Summary: Major Depressive Disorder
• Safety of Escitalopram in Patients With Social Anxiety Disorder
  Status: Active, not recruiting, Condition Summary: Social Anxiety Disorder
• Treatment for Bipolar Depression: Acute & Prophylactic Efficacy With Citalopram
  Status: Active, not recruiting, Condition Summary: Bipolar Disorder; Bipolar Depression
• Study of Escitalopram (Lexapro) for Improvement of Depressive Symptoms and Quality of Life in People With Multiple Sclerosis (MS) or Amyotrophic Lateral Sclerosis (ALS) Who Are Experiencing Depression
  Status: Recruiting, Condition Summary: Major Depression; Multiple Sclerosis; Amyotrophic Lateral Sclerosis
• Pharmacodynamics and Pharmacokinetics of Citalopram and Escitalopram
  Status: Recruiting, Condition Summary: Depression
• Development of Escitalopram Genomic Device by Using Candidate Gene Approach and Genome-Wide Scanning
  Status: Recruiting, Condition Summary: Depression; Antidepressant Response; Adverse Event
• Effectiveness of Escitalopram in the Treatment of Body Dysmorphic Disorder
  Status: Recruiting, Condition Summary: Anxiety Disorders; Somatoform Disorders
• Treatment Effects of Escitalopram (Lexapro®) on Generalized Anxiety Disorder in Patients With HIV and AIDS
  Status: Not yet recruiting, Condition Summary: Anxiety Disorders; HIV Infections
• A Clinical Trial to Evaluate the Efficacy and Safety of Generic Escitalopram in Depression
  Status: Recruiting, Condition Summary: Depression
• Cipralex in Treatment of Depressive Symptoms and Chronic Back Pain
  Status: Recruiting, Condition Summary: Low Back Pain; Depression
• Brain Effects of Escitalopram and Citalopram Using fMRI
  Status: Recruiting, Condition Summary: Healthy
• Escitalopram in Adult Patients With Major Depressive Disorder
  Status: Active, not recruiting, Condition Summary: Major Depressive Disorder
• Treatment of Post-Traumatic Stress Disorder With High Doses of Escitalopram
  Status: Enrolling by invitation, Condition Summary: Stress Disorders, Post Traumatic
• Responses of Myocardial Ischemia to Escitalopram Treatment
  Status: Recruiting, Condition Summary: Myocardial Ischemia

 

Get These Clinical Trials as a Newsfeed

Escitalopram:             

Current Research Literature on Escitalopram (Lexapro, Cipralex)

Here are abstracts for some of the latest research articles to have appeared on Escitalopram (Lexapro, Cipralex):

Altering endogenous extracellular serotonin concentrations can modulate network output in the neonatal mouse spinal cord.

J Physiol. 2009 Nov 2;
Dunbar MJ, Tran MA, Whelan PJ
Serotonin (5-HT) can potently activate and modulate spinal locomotor circuits in a variety of species. Many of these findings have been obtained by applying serotonin exogenously to the isolated spinal cord of in vitro preparations, which has the drawback of indiscriminately activating extrasynaptic receptors and neurons. To investigate the role of endogenously released serotonin in modulating locomotor networks, the selective serotonin reuptake inhibitor citalopram was used. Fictive locomotion was elicited by either electrical stimulation of the brainstem or the sacral 4 (S4) dorsal root. The addition of 20 muM of citalopram caudal to thoracic segment 5 (T5) had an overall inhibitory effect on the lumbar central pattern generator (CPG). Left-right and flexor-extensor coupling were significantly decreased, and there was also a phase shift in the flexor-extensor relationship. In addition, there was a significant decrease in burst amplitude. These effects were observed during both afferent and brainstem evoked fictive locomotion. When citalopram was added in the presence of 5-HT1A and 1B antagonists, the inhibitory effects were largely reversed. The remaining excitatory effects were mediated by 5-HT7 and 5-HT2 receptors. These results suggest that endogenous 5-HT release can modulate locomotor-like activity early in neonatal development.

Ziprasidone and Citalopram Use in Pregnancy and Lactation in a Woman With Psychotic Depression.

Am J Psychiatry. 2009 Nov; 166(11): 1298
Werremeyer A

Pharmacogenetics studies in STAR*D: strengths, limitations, and results.

Psychiatr Serv. 2009 Nov; 60(11): 1446-57
Laje G, Perlis RH, Rush AJ, McMahon FJ
Several lines of evidence support an important genetic contribution to the wide individual variation in therapeutic response to antidepressant medications. The Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study provided the largest cohort assembled to date of DNA from patients with nonpsychotic major depressive disorder, uniformly treated with citalopram and followed prospectively for up to 12 weeks. This pivotal study changed the face of pharmacogenetics research by increasing the sample size by an order of magnitude as well as by providing detailed prospective information about antidepressant response and tolerability. Several groups have identified markers in genes and tested the replication of previous findings of genes associated with outcome and side effects of antidepressant treatment. Variants in HTR2A, GRIK4, and KCNK2 were associated with citalopram treatment outcome. Replication was achieved in markers in the FKBP5 gene. Other findings in PDE11A and BDNF were not successfully replicated, and reports of potential confounders in previous associations with serotonin transporter variation (SLC6A4) were identified. Polymorphisms in pharmacokinetic genes involved in metabolism and transmembrane transport were also not associated with antidepressant response. Adverse events were also tested. Treatment-emergent suicidal ideation was associated with GRIK2, GRIA3, PAPLN, IL28RA, and CREB1. Sexual dysfunction was linked with variation in GRIN3A, GRIA1 GRIA3, and GRIK2. Reported and future findings of pharmacogenetics studies in STAR*D could help elucidate pathways involved in major depression and those pertinent to antidepressant outcome and side effects. Replication of these findings in independent samples could lead to the development of new treatments and to optimization of available treatments.

What did STAR*D teach us? Results from a large-scale, practical, clinical trial for patients with depression.

Psychiatr Serv. 2009 Nov; 60(11): 1439-45
Gaynes BN, Warden D, Trivedi MH, Wisniewski SR, Fava M, Rush AJ
The authors provide an overview of the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study (www.star-d.org), a large-scale practical clinical trial to determine which of several treatments are the most effective "next-steps" for patients with major depressive disorder whose symptoms do not remit or who cannot tolerate an initial treatment and, if needed, ensuing treatments. Entry criteria were broadly defined and inclusive, and patients were enrolled from psychiatric and primary care clinics. All participants began on citalopram and were managed by clinic physicians, who followed an algorithm-guided acute-phase treatment through five visits over 12 weeks. At the end of each sequence, patients whose depression had not fully remitted were eligible for subsequent randomized trials in a sequence of up to three clinical trials. In general, remission rates in the study clinics were lower than expected, suggesting the need for several steps to achieve remission for most patients. There was no clear medication "winner" for patients whose depression did not remit after one or more aggressive medication trials. Both switching and augmenting appeared to be reasonable options when an initial antidepressant treatment failed, although these two strategies could not be directly compared. Further, the likelihood of remission after two vigorous medication trials substantially decreased, and remission would likely require more complicated medication regimens for which the existing evidence base is quite thin. STAR*D demonstrated that inclusion of more real-world patients in clinical trials is both feasible and informative. Policy implications of the findings, as well as the study's limitations, are discussed.

A fatality due to cyproheptadine and citalopram.

J Anal Toxicol. 2009 Oct; 33(8): 564-7
Hargrove V, Molina DK
Cyproheptadine (Periactin) is a first-generation antihistamine available in over-the-counter cold medications and is used to treat allergic-type symptoms. Although antihistamines in general have long been known to cause serious side effects, especially when taken in overdose, few reports that specifically address cyproheptadine-related fatalities exist. A 42-year-old healthy female was found dead at her home with no anatomic cause of death and a recent history of suicidal ideations. Toxicology revealed cyproheptadine and citalopram in the femoral postmortem blood at concentrations of 0.49 and 2.3 mg/L, respectively. Vitreous, urine, and bile analysis were also performed, yielding concentrations of < 0.04 and 0.80 mg/L in the vitreous for cyproheptadine and citalopram, respectively; 0.23 and 8.2 mg/L in the urine; and 30.7 and 9.0 mg/L in the bile. The cause of death was determined to be cyproheptadine and citalopram intoxication, and the manner was ruled a suicide. Although cyproheptadine is widely available in the United States and Europe, there are only two published fatalities due to this antihistamine and only one that specifically cites blood and tissue concentrations. Therefore, this case study will be beneficial to the forensic toxicology community by providing additional information regarding postmortem interpretation.